Zimmer Biomet Holdings, Inc. - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Zimmer Biomet Holdings, Inc. is a global medical technology company designing, manufacturing, and marketing orthopedic reconstructive products, sports medicine, biologics, and robotic technologies. The company operates through three reportable segments: Americas, EMEA, and Asia Pacific. Notable recent developments include the integration of the Paragon 28 acquisition (completed April 2025) and the Monogram Technologies acquisition (completed October 2025).
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Net Sales | $2,177.0 million | $2,077.3 million | $4,263.7 million | $3,986.4 million |
| Operating Profit | $326.1 million | $300.0 million | $699.2 million | $592.3 million |
| Net Earnings (Zimmer Biomet) | $198.3 million | $152.8 million | $436.5 million | $334.9 million |
| Diluted EPS | $1.03 | $0.77 | $2.25 | $1.68 |
| Operating Margin | 15.0% | 14.4% | 16.4% | 14.9% |
| Effective Tax Rate | 21.8% | 31.7% | 21.3% | 25.9% |
Liquidity and Capital Resources
- Cash and Cash Equivalents: $410.0 million as of June 30, 2026 (down from $591.9 million at year-end 2025).
- Debt: Total debt outstanding was $7,479.0 million. Current portion of long-term debt is $1,201.5 million, including $571.5 million of Euro Notes due in December 2026 and $600.0 million of Senior Notes due in February 2027.
- Credit Facilities: The company has $1.5 billion available under a 2026 Five-Year Revolving Facility and $1.25 billion under a 2026 364-Day Revolving Facility. No borrowings were outstanding under these facilities as of June 30, 2026.
- Cash Flow: Net cash provided by operating activities was $807.2 million for the six months ended June 30, 2026. Net cash used in financing activities was $640.3 million, primarily driven by $500.8 million in share repurchases.
Material Changes and Drivers
- Revenue Growth: Net sales increased 4.8% in Q2 and 7.0% YTD compared to the prior year. Growth was driven by the Paragon 28 acquisition (contributing 0.7% in Q2 and 2.3% YTD), favorable foreign currency exchange rates, and increased sales of ROSA Robot and bone cement products.
- Profitability: Net earnings increased significantly due to higher sales, lower acquisition and integration costs (non-recurrence of significant 2025 Paragon 28 charges), reduced R&D spending, and restructuring savings.
- Tax Impact: The effective tax rate decreased to 21.3% YTD from 25.9% in the prior year, primarily due to the mix of earnings between U.S. and foreign locations.
- Tariff Refunds: The company recognized a favorable adjustment of approximately $30 million in the first half of 2026 related to probable refunds of U.S. tariffs paid in 2025 following a Supreme Court ruling.
- Segment Performance: Americas segment operating profit increased, while EMEA and Asia Pacific operating profits decreased slightly due to hedge-related losses and higher bad debt charges, respectively.
Guidance, Outlook, and Risks
- 2026 Outlook: Management expects full-year 2026 net sales growth of 3.9% to 4.9%. This is driven by market growth, new products, and the Paragon 28 acquisition, partially offset by pricing declines and go-to-market strategy changes.
- Operating Profit: Expected to increase in 2026 due to sales leverage, tariff refunds, and restructuring savings, though partially offset by inflation and higher net interest expense.
- Restructuring: The 2025 Restructuring Plan is expected to result in total pre-tax charges of approximately $155 million by the end of 2027. Approximately $147 million has been incurred through June 30, 2026.
- Key Risks:
- China Operations: Legal claims from displaced distributors in China regarding go-to-market strategy changes; potential material adverse impact on results.
- Goodwill Impairment: The Global Foot and Ankle reporting unit's fair value exceeded its carrying value by only approximately 5%, indicating a narrow margin for error.
- Contingent Consideration: Potential future payments for acquisitions (Paragon 28 and Monogram) range from $0 to $720 million based on revenue and regulatory milestones.
- Litigation: Accrued litigation liabilities were $137.9 million as of June 30, 2026.
Investor Verification Checklist
- Verify the status and potential payout of contingent consideration for Paragon 28 and Monogram acquisitions ($0 - $720 million range).
- Monitor the resolution of legal claims from distributors in China and the impact on the Asia Pacific segment.
- Assess the narrow margin of safety for the Global Foot and Ankle reporting unit goodwill impairment test.
- Confirm the timing and amount of U.S. tariff refunds received versus the $30 million recognized adjustment.
- Review the execution of the 2025 Restructuring Plan and the realization of the projected $175 million in annual operating expense savings.